Printer Friendly

Growth Continues for Novozymes.

COPENHAGEN, Denmark -- 2008 kicked off with high sales growth, leading to an upwards adjustment in local currencies. Expected sale of enzymes for detergents and feed significantly increased. Despite unfavorable exchange rates, the outlook for net profit 2008 in DKK is maintained.

Earnings development was good in the first quarter, and the developments in energy and raw material prices were in line with expectations. Overall, the financial results in the first quarter were very satisfactory, particularly given the generally unfavorable exchange rate movements.

* Novozymes' sales rose by 11% in local currencies in the first quarter of 2008. Calculated in DKK sales rose by 5% to MDKK 2,026 from MDKK 1,931 in 2007

* Operating profit rose by 4% to MDKK 372 from MDKK 359 in 2007. Adjusted for exchange rate movements, growth was approximately 13%

* The operating profit margin for the quarter was 18.4% against 18.6% in 2007

* Net profit for the period rose by 4% to MDKK 264 against MDKK 254 in 2007

* Earnings per share (diluted) were DKK 4.19 for the first quarter, an increase of 5%

* Free cash flow before acquisitions was MDKK 221 against MDKK 308 in 2007

* Return on invested capital (ROIC) fell to 19.3% from 22.4% in the first quarter of 2007

"The high growth rate is continuing in 2008," says Steen Riisgaard, President and CEO. "We have not seen, and there is no sign of, a slowdown in sales or earnings. In fact the first quarter was better than expected, so we are increasing our sales expectations for the year. However, the declining dollar is eroding growth and earnings in DKK. It is somewhat frustrating that the underlying business performance does not show in the results in DKK, because things are going really well."

Outlook for 2008

Novozymes is increasing its sales growth expectations for 2008 to 12-15% (from 11-14%) in local currencies, based on increased growth within detergent and feed enzymes. Novozymes is maintaining its outlook for net profit and free cash flow for the year in DKK. Assuming that exchange rates for the company's key currencies remain at their current low levels for the remainder of 2008, growth of 6-9% is expected in sales in DKK (previously 8-11%), with growth in operating profit in DKK of 1-4% (previously 2-5%). Note that growth in financial results is based on 2007, excluding one-off items.

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 24, 2008
Words:434
Previous Article:AMSC Sets Fourth-Quarter Reporting Date for May 8, 2008.
Next Article:Hubbell Reports First Quarter Results.
Topics:


Related Articles
Novel ideas from Novozymes: high-tech solutions for households and personal are manufacturers.
Fiske and Novozymes announce European partnership.
NOVOZYMES OPENS IOWA CENTER FOR ETHANOL/BIOFEUL RESEARCH.
Novozymes obtains United States patent.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters